Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Acadia Pharmaceuticals to $33 from $28 and keeps an Overweight rating on the shares. The firm came away from Acadia’s conference call discussing the FDA approval and early-launch strategy of DAYBUE for the treatment of Rett syndrome in adult and pediatric patients with further visibility on the pricing of DAYBUE and the company’s launch strategy, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $21 from $19.40 at Citi
- Acadia Pharmaceuticals price target raised to $28 from $25 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of DAYBUE for Rett syndrome
- Acadia Pharmaceuticals price target raised to $24 from $20 at Canaccord
- This ETF Has 67% Upside Potential, According to Analysts
